A Phase IIA Randomized Clinical Trial of a Multiclade HIV-1 DNA Prime Followed by a Multiclade rAd5 HIV-1 Vaccine Boost in Healthy Adults (HVTN204)
Gavin Churchyard(University of the Witwatersrand), Michelle Lally(Brown University), Zoe Moodie(Fred Hutch Cancer Center), Glenda Gray(South African Medical Research Council), Jean W. Pape(Gheskio Centers), Barney S. Graham(National Institutes of Health), Paul Goepfert(University of Maryland, Baltimore), Olivier Defawe(Infectious Disease Research Institute), Cecilia Morgan(Fred Hutch Cancer Center), Georgia D. Tomaras(National Institutes of Health), Linda‐Gail Bekker(Desmond Tutu HIV Foundation), Lawrence Corey(Fred Hutch Cancer Center), Gary J. Nabel(National Institutes of Health), Spyros A. Kalams(Vanderbilt University Medical Center), J. Peter Figueroa(University of the West Indies System), M. Juliana McElrath(Fred Hutch Cancer Center), Artur Olhovetchi Kalichman, Elizabeth M. Adams(National Institutes of Health), Lindsey R. Baden(Brigham and Women's Hospital), Mauro Schechter(Universidade Federal do Rio de Janeiro), Stephen C. De Rosa(University of Washington), John Hural(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Raphael Dolin(Beth Israel Deaconess Medical Center), Michael C. Keefer(University of Rochester Medical Center), William A. Blattner(Unknown), David C. Montefiori(Duke University), Doug Grove(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa)
Cited by 137
Related Papers
Integrated analysis of multimodal single-cell data
|Cell|2021|16.2k
Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus
|Cell|2020|4.5k
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
|New England Journal of Medicine|2021|2.6k
Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host
|New England Journal of Medicine|2020|1.4k